GSK plc (GSK) Form 6-K — Oct 26, 2026
GSK announced positive interim results from the phase II AZUR-1 trial, with 76% of evaluable patients (110/144) with MSI-H/dMMR locally advanced rectal cancer achieving a complete response on Jemperli (dostarlimab) monotherapy alone. No disease recurrences have been reported among responders after a median follow-up of more than two years, and the data supported a recent US approval of Jemperli in this indication.
Key figures
- Rash rate
- 22%
- Trial size
- n=154
- Fatigue rate
- 32%
- Median followup
- more than two years
- Complete response rate
- 76% (110/144)
- Ccr12 independent review
- 47% (54/116)
- Serious adverse reactions
- 20%
- Treatment discontinuation
- 3%
- Sustained ccr12 investigator
- 68% (98/144)
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.